悪性グリオーマに対するウイルス療法
腫瘍細胞のみで増殖し, 腫瘍細胞のみを死滅させる単純ヘルペスウイルスI型 (herpes simplex virus type 1 : HSV-1) を用いたウイルス療法は, 次世代のがん治療法として期待される. 第二世代がん治療用ウイルス (G207) は, 米国で悪性グリオーマを対象に第I相臨床試験が行われ, 脳腫瘍内投与の安全性が確認された. G207の安全性を維持しつつ, 腫瘍細胞におけるウイルス複製能を高め, 抗腫瘍免疫が増強するように開発された第三世代がん治療用ウイルス (G47Δ) は, 既存の治療では根治が得られない悪性グリオーマにとって有望な治療法として期待され, 本邦での開...
Saved in:
| Published in | 脳神経外科ジャーナル Vol. 22; no. 8; pp. 613 - 618 |
|---|---|
| Main Authors | , |
| Format | Journal Article |
| Language | Japanese |
| Published |
日本脳神経外科コングレス
2013
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 0917-950X 2187-3100 |
| DOI | 10.7887/jcns.22.613 |
Cover
| Abstract | 腫瘍細胞のみで増殖し, 腫瘍細胞のみを死滅させる単純ヘルペスウイルスI型 (herpes simplex virus type 1 : HSV-1) を用いたウイルス療法は, 次世代のがん治療法として期待される. 第二世代がん治療用ウイルス (G207) は, 米国で悪性グリオーマを対象に第I相臨床試験が行われ, 脳腫瘍内投与の安全性が確認された. G207の安全性を維持しつつ, 腫瘍細胞におけるウイルス複製能を高め, 抗腫瘍免疫が増強するように開発された第三世代がん治療用ウイルス (G47Δ) は, 既存の治療では根治が得られない悪性グリオーマにとって有望な治療法として期待され, 本邦での開発が進んでいる. |
|---|---|
| AbstractList | 腫瘍細胞のみで増殖し, 腫瘍細胞のみを死滅させる単純ヘルペスウイルスI型 (herpes simplex virus type 1 : HSV-1) を用いたウイルス療法は, 次世代のがん治療法として期待される. 第二世代がん治療用ウイルス (G207) は, 米国で悪性グリオーマを対象に第I相臨床試験が行われ, 脳腫瘍内投与の安全性が確認された. G207の安全性を維持しつつ, 腫瘍細胞におけるウイルス複製能を高め, 抗腫瘍免疫が増強するように開発された第三世代がん治療用ウイルス (G47Δ) は, 既存の治療では根治が得られない悪性グリオーマにとって有望な治療法として期待され, 本邦での開発が進んでいる. |
| Author | 伊藤, 元一 藤堂, 具紀 |
| Author_xml | – sequence: 1 fullname: 藤堂, 具紀 organization: 東京大学医科学研究所先端医療研究センター先端がん治療分野 – sequence: 1 fullname: 伊藤, 元一 organization: 東京大学医科学研究所先端医療研究センター先端がん治療分野 |
| BookMark | eNo9jz9Lw0AYxg-pYKyd_ByJ790lucsiSPEfFFwU3I7zcqcNNUrSxc1eRmeHLk6i0A4KToL4ZV6MX8MWRR54nuEHD_zWSae8Ki0hmxQiIaXYKkxZR4xFKeUrJGBUipBTgA4JIKMizBI4XSO9ui4AgDOeguAB4a2ftbfP6F-xmaGfYfOBzQNO5l8vnziZor9D_4T-EZs5-vfvqW_f7jfIqtOj2vb-tktO9naP-wfh4Gj_sL8zCAsGTIe545a5ROdWx2C4kFlCrYulzJiJHT0TIhU8j6WVksZ5ZliijQBH00U0zQ3vku3f36Ie63Orrqvhpa5ulK7GQzOyaimsGFNyWQvrf2AudKUKzX8AS45jhw |
| ContentType | Journal Article |
| Copyright | 2013 日本脳神経外科コングレス |
| Copyright_xml | – notice: 2013 日本脳神経外科コングレス |
| DOI | 10.7887/jcns.22.613 |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| EISSN | 2187-3100 |
| EndPage | 618 |
| ExternalDocumentID | article_jcns_22_8_22_613_article_char_ja |
| GroupedDBID | 2WC ALMA_UNASSIGNED_HOLDINGS JSF KQ8 OK1 RJT |
| ID | FETCH-LOGICAL-j202a-df3e2f5adea40c378951ef48892c4f1b77673d48e8814d9c25ac70f16161a1dc3 |
| ISSN | 0917-950X |
| IngestDate | Wed Sep 03 06:21:50 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | false |
| IsScholarly | true |
| Issue | 8 |
| Language | Japanese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-j202a-df3e2f5adea40c378951ef48892c4f1b77673d48e8814d9c25ac70f16161a1dc3 |
| OpenAccessLink | https://www.jstage.jst.go.jp/article/jcns/22/8/22_613/_article/-char/ja |
| PageCount | 6 |
| ParticipantIDs | jstage_primary_article_jcns_22_8_22_613_article_char_ja |
| PublicationCentury | 2000 |
| PublicationDate | 2013 |
| PublicationDateYYYYMMDD | 2013-01-01 |
| PublicationDate_xml | – year: 2013 text: 2013 |
| PublicationDecade | 2010 |
| PublicationTitle | 脳神経外科ジャーナル |
| PublicationTitleAlternate | 脳外誌 |
| PublicationYear | 2013 |
| Publisher | 日本脳神経外科コングレス |
| Publisher_xml | – name: 日本脳神経外科コングレス |
| References | 4) Ino Y, Saeki Y, Fukuhara H, Todo T : Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res 12 : 643-652, 2006. 5) Ino Y, Todo T : Clinical development of a third-generation oncolytic HSV-1 (G47Δ) for malignant glioma. Gene Therapy and Regulation 5 : 101-111, 2010. 16) Tsuji T, Nakamori M, Iwahashi M, Nakamura M, Ojima T, Iida T, Katsuda M, Hayata K, Ino Y, Todo T, Yamaue H : An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer. Int J Cancer 2012 Jun 22. doi : 10.1002/ijc. 27681., 2012. 1) Bennett JJ, Tjuvajev J, Johnson P, Doubrovin M, Akhurst T, Malholtra S, Hackman T, Balatoni J, Finn R, Larson SM, Federoff H, Blasberg R, Fong Y : Positron emission tomography imaging for herpes virus infection : Implications for oncolytic viral treatments of cancer. Nat Med 7 : 859-863, 2001. 12) Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL : Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1 : 938-943, 1995. 3) Fukuhara H, Ino Y, Kuroda T, Martuza RL, Todo T : Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res 65 : 10663-10668, 2005. 15) Todo T, Martuza RL, Rabkin SD, Johnson PA : Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A 98 : 6396-6401, 2001. 8) Kasai K, Saeki Y : DNA-based methods to prepare helper virus-free herpes amplicon vectors and versatile design of amplicon vector plasmids. Curr Gene Ther 6 : 303-314, 2006. 13) Saeki Y, Fraefel C, Ichikawa T, Breakefield XO, Chiocca EA : Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther 3 : 591-601, 2001. 10) Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Gillespie GY : Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 17 : 199-207, 2009. 9) Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL : Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma : results of a phase I trial. Gene Ther 7 : 867-874, 2000. 6) Ino Y, Todo T : [Oncolytic virus therapy for malignant brain tumors] . Brain Nerve 61 : 815-822, 2009. 7) Jacobs A, Tjuvajev JG, Dubrovin M, Akhurst T, Balatoni J, Beattie B, Joshi R, Finn R, Larson SM, Herrlinger U, Pechan PA, Chiocca EA, Breakefield XO, Blasberg RG : Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res 61 : 2983-2995, 2001. 17) White E, Bienemann A, Megraw L, Bunnun C, Gill S : Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery. Cancer Gene Ther 18 : 358-369, 2011. 2) Chiocca EA : Oncolytic viruses. Nat Rev Cancer 2 : 938-950, 2002. 11) Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM : Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252 : 854-856, 1991. 14) Todo T, Feigenbaum F, Rabkin SD, Lakeman F, Newsome JT, Johnson PA, Mitchell E, Belliveau D, Ostrove JM, Martuza RL : Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol Ther 2 : 588-595, 2000. |
| References_xml | – reference: 14) Todo T, Feigenbaum F, Rabkin SD, Lakeman F, Newsome JT, Johnson PA, Mitchell E, Belliveau D, Ostrove JM, Martuza RL : Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus. Mol Ther 2 : 588-595, 2000. – reference: 3) Fukuhara H, Ino Y, Kuroda T, Martuza RL, Todo T : Triple gene-deleted oncolytic herpes simplex virus vector double-armed with interleukin 18 and soluble B7-1 constructed by bacterial artificial chromosome-mediated system. Cancer Res 65 : 10663-10668, 2005. – reference: 9) Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL : Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma : results of a phase I trial. Gene Ther 7 : 867-874, 2000. – reference: 15) Todo T, Martuza RL, Rabkin SD, Johnson PA : Oncolytic herpes simplex virus vector with enhanced MHC class I presentation and tumor cell killing. Proc Natl Acad Sci U S A 98 : 6396-6401, 2001. – reference: 8) Kasai K, Saeki Y : DNA-based methods to prepare helper virus-free herpes amplicon vectors and versatile design of amplicon vector plasmids. Curr Gene Ther 6 : 303-314, 2006. – reference: 10) Markert JM, Liechty PG, Wang W, Gaston S, Braz E, Karrasch M, Nabors LB, Markiewicz M, Lakeman AD, Palmer CA, Parker JN, Whitley RJ, Gillespie GY : Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 17 : 199-207, 2009. – reference: 4) Ino Y, Saeki Y, Fukuhara H, Todo T : Triple combination of oncolytic herpes simplex virus-1 vectors armed with interleukin-12, interleukin-18, or soluble B7-1 results in enhanced antitumor efficacy. Clin Cancer Res 12 : 643-652, 2006. – reference: 11) Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM : Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252 : 854-856, 1991. – reference: 12) Mineta T, Rabkin SD, Yazaki T, Hunter WD, Martuza RL : Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nat Med 1 : 938-943, 1995. – reference: 13) Saeki Y, Fraefel C, Ichikawa T, Breakefield XO, Chiocca EA : Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther 3 : 591-601, 2001. – reference: 1) Bennett JJ, Tjuvajev J, Johnson P, Doubrovin M, Akhurst T, Malholtra S, Hackman T, Balatoni J, Finn R, Larson SM, Federoff H, Blasberg R, Fong Y : Positron emission tomography imaging for herpes virus infection : Implications for oncolytic viral treatments of cancer. Nat Med 7 : 859-863, 2001. – reference: 6) Ino Y, Todo T : [Oncolytic virus therapy for malignant brain tumors] . Brain Nerve 61 : 815-822, 2009. – reference: 2) Chiocca EA : Oncolytic viruses. Nat Rev Cancer 2 : 938-950, 2002. – reference: 5) Ino Y, Todo T : Clinical development of a third-generation oncolytic HSV-1 (G47Δ) for malignant glioma. Gene Therapy and Regulation 5 : 101-111, 2010. – reference: 7) Jacobs A, Tjuvajev JG, Dubrovin M, Akhurst T, Balatoni J, Beattie B, Joshi R, Finn R, Larson SM, Herrlinger U, Pechan PA, Chiocca EA, Breakefield XO, Blasberg RG : Positron emission tomography-based imaging of transgene expression mediated by replication-conditional, oncolytic herpes simplex virus type 1 mutant vectors in vivo. Cancer Res 61 : 2983-2995, 2001. – reference: 16) Tsuji T, Nakamori M, Iwahashi M, Nakamura M, Ojima T, Iida T, Katsuda M, Hayata K, Ino Y, Todo T, Yamaue H : An armed oncolytic herpes simplex virus expressing thrombospondin-1 has an enhanced in vivo antitumor effect against human gastric cancer. Int J Cancer 2012 Jun 22. doi : 10.1002/ijc. 27681., 2012. – reference: 17) White E, Bienemann A, Megraw L, Bunnun C, Gill S : Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery. Cancer Gene Ther 18 : 358-369, 2011. |
| SSID | ssj0003236073 ssib023160918 ssib002223908 ssib000937641 |
| Score | 1.9193351 |
| Snippet | 腫瘍細胞のみで増殖し, 腫瘍細胞のみを死滅させる単純ヘルペスウイルスI型 (herpes simplex virus type 1 : HSV-1) を用いたウイルス療法は, 次世代のがん治療法として期待される. 第二世代がん治療用ウイルス (G207) は, 米国で悪性グリオーマを対象に第I相臨床試験が行われ,... |
| SourceID | jstage |
| SourceType | Publisher |
| StartPage | 613 |
| SubjectTerms | G47Δ malignant glioma oncolytic virus therapy |
| Title | 悪性グリオーマに対するウイルス療法 |
| URI | https://www.jstage.jst.go.jp/article/jcns/22/8/22_613/_article/-char/ja |
| Volume | 22 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| ispartofPNX | 脳神経外科ジャーナル, 2013, Vol.22(8), pp.613-618 |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR09b9UwMCplYUFFgPhWBzymOHYSO2MSpapAICG10tsi52t4Q4vQ68JE80Zmhi6dEEivA0hMSIg_Y_H4G9w5cV6ADuUt0eV8Pt_l_HJ3fvbFcR4XFfjRymtcGVRYVFsJV1WN5yp4E8qipA01RVyfvwj3Dvynk2CyceVotGvpeFbslG8uPFeyjlUBB3bFU7L_YdmBKSAABvvCFSwM10vZmGQhkYzEsQEoiQXJOGISagBumrilMZgk7YEoM4BH4oRkAYl3SWIxUdT3kontHlrAt5xtUwLEArsADGIkwDkYh7wkk0T6iAeyODDjCpIERKZmXJ9EoWkCJp7lKe0o_G-xZTwIYCcLjhAJIxrwo8gAJg7eyIAkwgwHITNd0fvIDznZjit64IzN0tL3KyLdUVYze1HLyKiCQEridC0VB834P0ZLh0c7Xkn18F9wOulcqsFB4ITLv5SOHQ1jox-UHHmNsNeh7u_kRb4Nt32ibythyjK2M_T5o1h4PxVzpMoZyyVegDS3DXiWL59CQnGVCeHhHthnL0fxOASr4Tg-huAxWhV_glwgBG3lsIjJGQ9pt4vDPoTuDCwK-2QkKsR3U8h27E5JE7ztbznX-6xrO-7Eu-FsTNVNhy_bxfLtJ91-0fOFbhd6_l3Pz_TJ-c_PP_TJqW7f6fajbj_o-bluv_06bZdf399yDnaz_XTP7b8h4k4ZZcqtGl6zJlBVrXxaciEho6gb8FoRK_3GK7CYFa98WUvp-VVUskCVgjaQB4We8qqS33Y2D48O6zvOdgG-UAVlwfwa3B6LVMOwdpJsaFNBihredUSnY_6qKxSTX9Ya99bued-5xsz3WXBN8IGzOXt9XD-EKHlWPDKW_Q33h5Il |
| linkProvider | Colorado Alliance of Research Libraries |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E6%82%AA%E6%80%A7%E3%82%B0%E3%83%AA%E3%82%AA%E3%83%BC%E3%83%9E%E3%81%AB%E5%AF%BE%E3%81%99%E3%82%8B%E3%82%A6%E3%82%A4%E3%83%AB%E3%82%B9%E7%99%82%E6%B3%95&rft.jtitle=%E8%84%B3%E7%A5%9E%E7%B5%8C%E5%A4%96%E7%A7%91%E3%82%B8%E3%83%A3%E3%83%BC%E3%83%8A%E3%83%AB&rft.au=%E8%97%A4%E5%A0%82%2C+%E5%85%B7%E7%B4%80&rft.au=%E4%BC%8A%E8%97%A4%2C+%E5%85%83%E4%B8%80&rft.date=2013&rft.pub=%E6%97%A5%E6%9C%AC%E8%84%B3%E7%A5%9E%E7%B5%8C%E5%A4%96%E7%A7%91%E3%82%B3%E3%83%B3%E3%82%B0%E3%83%AC%E3%82%B9&rft.issn=0917-950X&rft.eissn=2187-3100&rft.volume=22&rft.issue=8&rft.spage=613&rft.epage=618&rft_id=info:doi/10.7887%2Fjcns.22.613&rft.externalDocID=article_jcns_22_8_22_613_article_char_ja |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0917-950X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0917-950X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0917-950X&client=summon |